“…[6][7][8] However, conventional sonosensitizers suffer from limitations including inferior biocompatibility, rapid degradation, and low ROS production, leading to low SDT efficiency. 9,10 To address these issues, researchers have explored the use of nanocarriers for delivering sonosensitizers to enhance their therapeutic efficacy. Owing to their biological characteristics, for example, small particle sizes and large surface-to-body ratios, nanomaterials can efficiently carry small drugs to tumor areas.…”